Chemokines and chemokine receptors: new insights into cancer-related inflammation - PubMed (original) (raw)
Review
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Gwendal Lazennec et al. Trends Mol Med. 2010 Mar.
Abstract
Chemokines are involved in cellular interactions and tropism in situations frequently associated with inflammation. Recently, the importance of chemokines and chemokine receptors in inflammation associated with carcinogenesis has been highlighted. Increasing evidence suggests that chemokines are produced by tumor cells as well as by cells of the tumor microenvironment including cancer-associated fibroblasts (CAFs), mesenchymal stem cells (MSCs), endothelial cells, tumor-associated macrophages (TAMs) and more recently tumor-associated neutrophils (TANs). In addition to affecting tumor cell proliferation, angiogenesis and metastasis, chemokines also seem to modulate senescence and cell survival. Here, we review recent progress on the roles of chemokines and chemokine receptors in cancer-related inflammation, and discuss the mechanisms underlying chemokine action in cancer that might facilitate the development of novel therapies in the future.
Copyright 2010 Elsevier Ltd. All rights reserved.
Figures
Figure 1. Repertoire of chemokines and chemokine receptors expressed in cancer tissues
Close interactions occur between cancer cells and cells of the tumor microenvironment, including endothelial cells, cancer-associated fibroblasts (CAFs), mesenchymal stem cells (MSCs), myeloid cells and tumor-associated neutrophils (TAN). Cancer cells produce a variety of chemokines that can modulate the biological properties not only of these cells but also those of associated stromal cells. Similarly, the cells of the tumor microenvironment also provide a source of chemokines that can alter the functions of cancer cells.
Figure 2. Multiple chemokines affect angiogenesis, proliferation, invasion, apoptosis, and senescence
Chemokines can modulate cancer cell proliferation, apoptosis, senescence and invasion and participate in tumor angiogenesis as well as leukocyte infiltration. Cancer cells are shown in red. Recent findings suggest that CXCR7 could be involved in the control of proliferation. CXCR7 could also inhibit apoptosis, whereas CCL2 impedes autophagic death. Senescence is also tightly regulated by CXCR2 and its ligands CXCL1 and CXCL8. Decoy receptors such as DARC and D6 could regulate angiogenesis negatively. Other chemokines such as CXCL1, CXCL8 and their receptor CXCR2 promote angiogenesis. CXCL1 is induced by prostaglandin E2 (PGE2), whereas CXCL8 is negatively regulated by prolylhydroxylase 2 (PHD2). Homing of cancer cells to specific metastatic sites is tightly controlled by chemokines CXCL1,8, 12, CCL5, CCL19, 21, 25, 27 and chemokine receptors CCR5, 7, 9, 10 and CX3CR1. CXCL12 levels are induced by Src (a non-receptor cytoplasmic tyrosine kinase) and in turn can modulate metastasis. CCR7, whose expression is controlled by Notch1 and interstitial flow, plays an active role in metastasis. Several reports have indicated the central role played by TGFβ, which can induce CXCL12 expression, but are also induces CCL2, 5, CXCR2 and CXCR4 expression. In turn, these chemokines and chemokine receptors promote inflammatory cell infiltration. By contrast, TGFβ down-regulates CXCL1, 5, 8, CCL9 and CCR1 levels, which acts to further modulate leukocyte infiltration.
Figure 3. Current and future intervention points for chemokine- and chemokine receptor-based therapies in cancer
The chemokines or chemokine receptors currently targeted in clinical trials are shown in black. Novel candidates for therapeutic targets, based on recent studies of their actions in different stages of cancer development, are shown in red,
Box 1 Figure I. Chemokines and chemokine receptor families[RE3]
Most chemokines can interact with multiple receptors, and a single receptor can interact with multiple chemokines. This is the case for most CC (red) and CXC (green) chemokines. Decoy receptors (black) can also bind multiple chemokines. On the other hand, a minority of receptors (blue) have only one ligand.
Similar articles
- Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy.
Morein D, Erlichman N, Ben-Baruch A. Morein D, et al. Front Immunol. 2020 Jun 4;11:952. doi: 10.3389/fimmu.2020.00952. eCollection 2020. Front Immunol. 2020. PMID: 32582148 Free PMC article. Review. - Role of chemokines in tumor growth.
Raman D, Baugher PJ, Thu YM, Richmond A. Raman D, et al. Cancer Lett. 2007 Oct 28;256(2):137-65. doi: 10.1016/j.canlet.2007.05.013. Epub 2007 Jul 12. Cancer Lett. 2007. PMID: 17629396 Free PMC article. Review. - Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Song N, Cui K, Zeng L, Li M, Fan Y, Shi P, Wang Z, Su W, Wang H. Song N, et al. Eur J Pharmacol. 2024 Mar 15;967:176357. doi: 10.1016/j.ejphar.2024.176357. Epub 2024 Feb 1. Eur J Pharmacol. 2024. PMID: 38309677 Review. - Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW, Elbaz M, Ahirwar DK, Ganju RK. Nasser MW, et al. Cancer Lett. 2015 Aug 28;365(1):11-22. doi: 10.1016/j.canlet.2015.05.002. Epub 2015 May 8. Cancer Lett. 2015. PMID: 25963887 Free PMC article. Review. - Chemokines, chemokine receptors, and cancer metastasis.
Kakinuma T, Hwang ST. Kakinuma T, et al. J Leukoc Biol. 2006 Apr;79(4):639-51. doi: 10.1189/jlb.1105633. Epub 2006 Feb 14. J Leukoc Biol. 2006. PMID: 16478915 Review.
Cited by
- Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications.
Yang M, Chen G, Gao K, Wang Y. Yang M, et al. Front Oncol. 2021 Mar 16;11:622752. doi: 10.3389/fonc.2021.622752. eCollection 2021. Front Oncol. 2021. PMID: 33796460 Free PMC article. - Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression.
Yang SB, Han F, Wu JH, Zhao Z, Zhan W. Yang SB, et al. Oncol Lett. 2016 Aug;12(2):1477-1484. doi: 10.3892/ol.2016.4790. Epub 2016 Jun 28. Oncol Lett. 2016. PMID: 27446456 Free PMC article. - CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.
Chen N, Jiang X, Wang J, Wu T, Cheng B, Xia J. Chen N, et al. Tumour Biol. 2016 Jan;37(1):567-75. doi: 10.1007/s13277-015-3803-6. Epub 2015 Aug 2. Tumour Biol. 2016. PMID: 26232325 - Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures.
Sun Y. Sun Y. Med Res Rev. 2015 Mar;35(2):408-36. doi: 10.1002/med.21338. Epub 2015 Jan 15. Med Res Rev. 2015. PMID: 25588753 Free PMC article. Review. - Monocyte chemotactic protein-1 promotes the proliferation and invasion of osteosarcoma cells and upregulates the expression of AKT.
Chen Q, Sun W, Liao Y, Zeng H, Shan L, Yin F, Wang Z, Zhou Z, Hua Y, Cai Z. Chen Q, et al. Mol Med Rep. 2015 Jul;12(1):219-25. doi: 10.3892/mmr.2015.3375. Epub 2015 Feb 18. Mol Med Rep. 2015. PMID: 25695619 Free PMC article.
References
- Binder NB, et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med. 2009;15:417–424. - PubMed
- Trifari S, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864–871. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- IK6 BX005225/BX/BLRD VA/United States
- CA098807/CA/NCI NIH HHS/United States
- R01 CA098807/CA/NCI NIH HHS/United States
- R01 CA034590/CA/NCI NIH HHS/United States
- R01 CA098807-05/CA/NCI NIH HHS/United States
- R01 CA116021/CA/NCI NIH HHS/United States
- R01 CA116021-05/CA/NCI NIH HHS/United States
- CA116021/CA/NCI NIH HHS/United States
- R01 CA034590-27/CA/NCI NIH HHS/United States
- CA34590/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources